文献速递胃肠外科围术期管理与 ERAS

减重手术后新发持续性阿片类药物使用:系统综述与合并比例荟萃分析

New persistent opioid use after bariatric surgery: a systematic review and pooled proportion meta-analysis.
PubMed 文献 · Surg Endosc · 2022-05-09

该系统综述纳入8项研究,评估减重手术后新发持续性阿片使用(NPOU)的患病率及相关因素。4项研究报告NPOU合并患病率为6.0%(95%CI 4.0-7.0%)。既往物质使用、术前精神健康障碍、公共医疗保险及术后严重并发症和围术期阿片使用与NPOU相关。

要点

  • 减重术后NPOU合并患病率为6.0%(95%CI 4.0-7.0%)。
  • 既往物质使用和术前精神健康障碍增加NPOU风险。
  • 术后严重并发症和围术期阿片使用与NPOU相关。

核心结论

  • NPOU是减重手术后不常见但重要的并发症,合并患病率为6.0%(95%CI 4.0-7.0%)。
  • 既往物质滥用、精神健康障碍和公共医疗保险使用增加NPOU风险。
  • 手术因素中并发症和围术期阿片使用与NPOU相关。

研究设计与样本

  • 系统综述与合并比例荟萃分析,检索MEDLINE、Embase、Scopus、Web of Science和Cochrane数据库(2021年8月)。
  • 纳入报告减重手术后>90天新发阿片使用的英文研究,排除摘要、非英文、动物、n<5及儿科研究。
  • 共检索2113项研究,8项符合纳入标准,其中4项报告NPOU率用于合并分析。

主要发现

  • 4项研究报告NPOU合并患病率为6.0%(95%CI 4.0-7.0%)。
  • 与NPOU相关的患者因素包括既往物质使用(烟草、酒精、其他处方镇痛药)、术前精神健康障碍(焦虑、情绪障碍、进食障碍)和公共医疗保险。
  • 与NPOU相关的手术因素包括术后严重并发症和住院期间阿片使用(围术期或术后)。
  • 因报告异质性,未能完成相关因素的荟萃分析。

关键数值与推荐

  • NPOU定义为术后>90天新发阿片使用。
  • NPOU合并患病率为6.0%(95%CI 4.0-7.0%),基于4项研究。

临床怎么用

  • 减重手术患者应评估既往物质使用和术前精神健康障碍以识别NPOU高风险者。
  • 关注公共医疗保险患者及发生严重术后并发症或围术期使用阿片者的NPOU风险。
  • 需研究减少高风险人群NPOU的干预技术。

局限性

  • 仅4项研究提供NPOU率用于合并分析。
  • 相关因素因报告异质性未能进行荟萃分析。
  • 检索截至2021年8月,可能遗漏后续研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Increasing evidence suggests surgical patients are at risk for developing new, persistent opioid use (NPOU) following surgery. This risk may be heightened for patients undergoing bariatric surgery. Few studies have evaluated this important long-term outcome and little is known about the rate of NPOU, or factors associated with NPOU for bariatric surgery patients. METHODS AND PROCEDURE: We conducted a systematic review of MEDLINE, Embase, Scopus, Web of Science, and Cochrane databases in August 2021. Studies were reviewed and data extracted independently by two reviewers following MOOSE guidelines. Studies evaluating bariatric surgery patients reporting NPOU, defined as new opioid use > 90 days after surgery, were included. Abstracts, non-English, animal, n < 5, and pediatric studies were excluded. Primary outcome was NPOU prevalence, and secondary outcomes were patient and surgical factors associated with NPOU. Factors associated with NPOU are reported from findings of individual studies; meta-analysis could not be completed due to heterogeneity of reporting. RESULTS: We retrieved a total of 2113 studies with 8 meeting inclusion criteria. In studies reporting NPOU rates (n = 4 studies), pooled prevalence was 6.0% (95% CI 4.0-7.0%). Patient characteristics reported by studies to be associated with NPOU included prior substance use (tobacco, alcohol, other prescription analgesics), preoperative mental health disorder (anxiety, mood disorders, eating disorders), and public health insurance. Surgical factors associated with NPOU included severe post-operative complications and in-hospital opioid use (peri- or post operatively). CONCLUSIONS: NPOU is an uncommon but important complication following bariatric surgery, with patient factors including prior substance abuse, mental health disorders, and use of public health insurance placing patients at increased risk, and surgical factors being complications and peri-operative opioid use. Studies evaluating techniques to reduce NPOU in these high-risk populations are needed.

来源:Surg Endosc,查看原文。版权归原作者所有。

引用

  1. Nasser K, Verhoeff K, Mocanu V, et al. New persistent opioid use after bariatric surgery: a systematic review and pooled proportion meta-analysis. Surg Endosc. 2022. PMID: 35534738. doi:10.1007/s00464-022-09291-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。